Free Trial

Kailera Therapeutics (KLRA) 10K Form and Latest SEC Filings 2026

$22.56 +1.09 (+5.08%)
As of 03:33 PM Eastern

Latest Kailera Therapeutics SEC Filings & Recent Activity

Kailera Therapeutics (NASDAQ:KLRA) has submitted 48+ documents to the U.S. Securities and Exchange Commission (SEC) since 2026. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13D submitted on April 23, 2026.

Form 4
Kailera Therapeutics, Inc. Reports Ownership Change on Apr. 22, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Kailera Therapeutics Files Current Report on Apr. 20, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Kailera Therapeutics SEC Filing History

Browse Kailera Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/23/2026 7:01 PM
BCLS Fund IV Investments, L.P. (2015454) Filed by
Kailera Therapeutics (2096997) Subject
Form SCHEDULE 13D
04/23/2026 6:34 PM
BCPE Perseus Investor, LP (2100174) Filed by
Kailera Therapeutics (2096997) Subject
Form SCHEDULE 13D
04/22/2026 3:15 PM
Kailera Therapeutics (2096997) Issuer
RTW INVESTMENTS, LP (1493215) Reporting
WONG RODERICK (1493280) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/22/2026 5:03 AM
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (2080343) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 5:08 PM
Kailera Therapeutics (2096997) Issuer
Koppel Adam (1578965) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 5:10 PM
Bain Capital Fund XIV, L.P. (2016381) Reporting
BAIN CAPITAL INVESTORS LLC (1040508) Reporting
Bain Capital XIV General Partner, LLC (2016388) Reporting
BCPE Perseus Investor GP, LLC (2100155) Reporting
BCPE Perseus Investor, LP (2100174) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 5:00 PM
Kailera Therapeutics (2096997) Issuer
Kaplan Andrew T. (1752059) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 5:01 PM
Bain Capital Life Sciences Fund IV, L.P. (1996979) Reporting
Bain Capital Life Sciences Investors, LLC (1703031) Reporting
Bain Capital Life Sciences IV General Partner, LLC (1996931) Reporting
BCLS Fund IV Investments GP, LLC (2015967) Reporting
BCLS Fund IV Investments, L.P. (2015454) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:08 PM
Kailera Therapeutics (2096997) Issuer
Wasserman Scott M. (2118767) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:10 PM
Kailera Therapeutics (2096997) Issuer
MACKAY MARTIN (1414815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:13 PM
Coleman Jamie Beth (2118765) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:13 PM
Kailera Therapeutics (2096997) Issuer
MILLIGAN JOHN F (1191589) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:14 PM
Burgess Paul D. (1744627) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:18 PM
Kailera Therapeutics (2096997) Issuer
Renaud Ronald C JR (1354434) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:19 PM
Akamine Scott (1816720) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:19 PM
Cloghessy Paula (1744682) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:01 PM
Kailera Therapeutics (2096997) Issuer
Pagan Douglas W. (1628880) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:04 PM
Clyburn Frank (1763963) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 4:05 PM
Hite Christopher (1814238) Reporting
Kailera Therapeutics (2096997) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 3:19 PM
Kailera Therapeutics (2096997) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/17/2026 3:06 PM
Kailera Therapeutics (2096997) Filer
Form 424B4
04/16/2026 11:15 PM
Kailera Therapeutics (2096997) Filer
Form EFFECT
04/17/2026 5:02 AM
Kailera Therapeutics (2096997) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
04/16/2026 7:24 PM
Bain Capital Life Sciences Fund IV, L.P. (1996979) Reporting
Bain Capital Life Sciences Investors, LLC (1703031) Reporting
Bain Capital Life Sciences IV General Partner, LLC (1996931) Reporting
BCLS Fund IV Investments GP, LLC (2015967) Reporting
BCLS Fund IV Investments, L.P. (2015454) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 7:24 PM
Bain Capital Fund XIV, L.P. (2016381) Reporting
BAIN CAPITAL INVESTORS LLC (1040508) Reporting
Bain Capital XIV General Partner, LLC (2016388) Reporting
BCPE Perseus Investor GP, LLC (2100155) Reporting
BCPE Perseus Investor, LP (2100174) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 7:27 PM
Kailera Therapeutics (2096997) Issuer
Koppel Adam (1578965) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 7:29 PM
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (2080343) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 7:19 PM
Kailera Therapeutics (2096997) Issuer
Kaplan Andrew T. (1752059) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:39 PM
Hite Christopher (1814238) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:40 PM
Kailera Therapeutics (2096997) Issuer
Liu Yuting (2119231) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:40 PM
Kailera Therapeutics (2096997) Issuer
MACKAY MARTIN (1414815) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:41 PM
Kailera Therapeutics (2096997) Issuer
RTW INVESTMENTS, LP (1493215) Reporting
WONG RODERICK (1493280) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:42 PM
Coleman Jamie Beth (2118765) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:44 PM
Kailera Therapeutics (2096997) Issuer
Pagan Douglas W. (1628880) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:45 PM
Kailera Therapeutics (2096997) Issuer
Wasserman Scott M. (2118767) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:49 PM
Burgess Paul D. (1744627) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:27 PM
Kailera Therapeutics (2096997) Issuer
MILLIGAN JOHN F (1191589) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:30 PM
Akamine Scott (1816720) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:30 PM
Clyburn Frank (1763963) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:35 PM
Kailera Therapeutics (2096997) Issuer
Renaud Ronald C JR (1354434) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 6:35 PM
Cloghessy Paula (1744682) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 5:58 PM
Kailera Therapeutics (2096997) Filer
Form S-1MEF
04/16/2026 4:54 PM
CANADA PENSION PLAN INVESTMENT BOARD (1283718) Reporting
CPP Investment Board Private Holdings (4) Reporting
Kailera Therapeutics (2096997) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/16/2026 4:45 PM
Kailera Therapeutics (2096997) Issuer
Stuart Partners, LLC (2128737) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/15/2026 2:30 PM
Kailera Therapeutics (2096997) Filer
Form CERT
04/14/2026 3:06 PM
Kailera Therapeutics (2096997) Filer
Form 8-A12B
04/13/2026 5:12 AM
Kailera Therapeutics (2096997) Filer
Form S-1/A
03/27/2026 3:02 PM
Kailera Therapeutics (2096997) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Kailera Therapeutics SEC Filings - Frequently Asked Questions

Kailera Therapeutics (KLRA) has submitted 48+ filings to the SEC since 2026. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form SCHEDULE 13D submitted on April 23, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:KLRA) was last updated on 5/11/2026 by MarketBeat.com Staff.
From Our Partners